PandemieGrippaleV1, PubMed, Curation, bibRecord, 000440

Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.

Identifieur interne : 000440 ( PubMed/Curation ); précédent : 000439; suivant : 000441

Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.

Auteurs : Jihyun Yang [Corée du Sud] ; Sang-Mu Shim [Corée du Sud] ; Thi Quyen Nguyen [Corée du Sud] ; Eun-Ha Kim [Corée du Sud] ; Kwang Kim [Corée du Sud] ; Yong Taik Lim [Corée du Sud] ; Moon-Hee Sung [Corée du Sud] ; Richard Webby [États-Unis] ; Haryoung Poo [Corée du Sud]

Source :

Scientific reports [ 2045-2322 ] ; 2017.

RBID : pubmed:28322289

Descripteurs français

English descriptors

KwdEn :
- Adjuvants, Immunologic, Animals, Antigen Presentation (immunology), Antigens, Viral (immunology), Chitosan (analogs & derivatives), Chitosan (chemistry), Cross Reactions (immunology), Dendritic Cells (immunology), Dendritic Cells (metabolism), Disease Models, Animal, Ferrets, Histocompatibility Antigens Class I (immunology), Histocompatibility Antigens Class I (metabolism), Humans, Immunity, Cellular, Immunogenicity, Vaccine, Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (chemistry), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Mice, Orthomyxoviridae Infections (mortality), Orthomyxoviridae Infections (prevention & control), Phagosomes (metabolism), Polyglutamic Acid (analogs & derivatives), Polyglutamic Acid (chemistry).
MESH :
- chemical , analogs & derivatives : Chitosan, Polyglutamic Acid.
- chemical , chemistry : Chitosan, Influenza Vaccines, Polyglutamic Acid.
- chemical , immunology : Antigens, Viral, Histocompatibility Antigens Class I, Influenza Vaccines.
- chemical , metabolism : Histocompatibility Antigens Class I.
- chemical : Adjuvants, Immunologic.
- immunology : Antigen Presentation, Cross Reactions, Dendritic Cells, Influenza A Virus, H1N1 Subtype.
- metabolism : Dendritic Cells, Phagosomes.
- mortality : Orthomyxoviridae Infections.
- prevention & control : Influenza, Human, Orthomyxoviridae Infections.
- Animals, Disease Models, Animal, Ferrets, Humans, Immunity, Cellular, Immunogenicity, Vaccine, Mice.

Abstract

In 2009, the global outbreak of an influenza pandemic emphasized the need for an effective vaccine adjuvant. In this study, we examined the efficacy of poly-γ-glutamic acid/chitosan (PC) nanogel as an adjuvant for the influenza vaccine. PC nanogel significantly enhanced antigen-specific cross-presentation and cytotoxic T lymphocyte (CTL) activity. Compared with alum, the protective efficacy of the pandemic H1N1 influenza (pH1N1) vaccine was substantially increased by PC nanogel, with increased hemagglutination-inhibition titers, CTL activity, and earlier virus clearance after homologous and heterosubtypic [A/Philippines/2/82 (H3N2)] virus challenges. However, CD8⁺ T cell-depleted mice displayed no protection against the heterosubtypic virus challenge after immunization with PC nanogel-adjuvanted pH1N1 vaccine. We also observed that using PC nanogel as a vaccine adjuvant had a dose-sparing effect and significantly enhanced the long-lasting protection of the pH1N1 vaccine. Together, these results suggest that PC nanogel is a promising vaccine adjuvant that could broadly prevent influenza virus infection.

DOI: 10.1038/srep44839
PubMed: 28322289

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000440

Links to Exploration step

pubmed:28322289

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.</title>
<author><name sortKey="Yang, Jihyun" sort="Yang, Jihyun" uniqKey="Yang J" first="Jihyun" last="Yang">Jihyun Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shim, Sang Mu" sort="Shim, Sang Mu" uniqKey="Shim S" first="Sang-Mu" last="Shim">Sang-Mu Shim</name>
<affiliation wicri:level="1"><nlm:affiliation>Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Thi Quyen" sort="Nguyen, Thi Quyen" uniqKey="Nguyen T" first="Thi Quyen" last="Nguyen">Thi Quyen Nguyen</name>
<affiliation wicri:level="1"><nlm:affiliation>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Eun Ha" sort="Kim, Eun Ha" uniqKey="Kim E" first="Eun-Ha" last="Kim">Eun-Ha Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Kwang" sort="Kim, Kwang" uniqKey="Kim K" first="Kwang" last="Kim">Kwang Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>BioLeaders Corporation, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>BioLeaders Corporation, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lim, Yong Taik" sort="Lim, Yong Taik" uniqKey="Lim Y" first="Yong Taik" last="Lim">Yong Taik Lim</name>
<affiliation wicri:level="1"><nlm:affiliation>Sungkyunkwan Advanced Institute of Nanotechnology (SAINT) and Department of Chemical Engineering, Sungkyunkwan University Suwon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Sungkyunkwan Advanced Institute of Nanotechnology (SAINT) and Department of Chemical Engineering, Sungkyunkwan University Suwon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sung, Moon Hee" sort="Sung, Moon Hee" uniqKey="Sung M" first="Moon-Hee" last="Sung">Moon-Hee Sung</name>
<affiliation wicri:level="1"><nlm:affiliation>BioLeaders Corporation, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>BioLeaders Corporation, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Webby, Richard" sort="Webby, Richard" uniqKey="Webby R" first="Richard" last="Webby">Richard Webby</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Virology, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Virology, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poo, Haryoung" sort="Poo, Haryoung" uniqKey="Poo H" first="Haryoung" last="Poo">Haryoung Poo</name>
<affiliation wicri:level="1"><nlm:affiliation>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28322289</idno>
<idno type="pmid">28322289</idno>
<idno type="doi">10.1038/srep44839</idno>
<idno type="wicri:Area/PubMed/Corpus">000440</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000440</idno>
<idno type="wicri:Area/PubMed/Curation">000440</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000440</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.</title>
<author><name sortKey="Yang, Jihyun" sort="Yang, Jihyun" uniqKey="Yang J" first="Jihyun" last="Yang">Jihyun Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shim, Sang Mu" sort="Shim, Sang Mu" uniqKey="Shim S" first="Sang-Mu" last="Shim">Sang-Mu Shim</name>
<affiliation wicri:level="1"><nlm:affiliation>Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Thi Quyen" sort="Nguyen, Thi Quyen" uniqKey="Nguyen T" first="Thi Quyen" last="Nguyen">Thi Quyen Nguyen</name>
<affiliation wicri:level="1"><nlm:affiliation>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Eun Ha" sort="Kim, Eun Ha" uniqKey="Kim E" first="Eun-Ha" last="Kim">Eun-Ha Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Kwang" sort="Kim, Kwang" uniqKey="Kim K" first="Kwang" last="Kim">Kwang Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>BioLeaders Corporation, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>BioLeaders Corporation, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lim, Yong Taik" sort="Lim, Yong Taik" uniqKey="Lim Y" first="Yong Taik" last="Lim">Yong Taik Lim</name>
<affiliation wicri:level="1"><nlm:affiliation>Sungkyunkwan Advanced Institute of Nanotechnology (SAINT) and Department of Chemical Engineering, Sungkyunkwan University Suwon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Sungkyunkwan Advanced Institute of Nanotechnology (SAINT) and Department of Chemical Engineering, Sungkyunkwan University Suwon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sung, Moon Hee" sort="Sung, Moon Hee" uniqKey="Sung M" first="Moon-Hee" last="Sung">Moon-Hee Sung</name>
<affiliation wicri:level="1"><nlm:affiliation>BioLeaders Corporation, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>BioLeaders Corporation, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Webby, Richard" sort="Webby, Richard" uniqKey="Webby R" first="Richard" last="Webby">Richard Webby</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Virology, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Virology, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poo, Haryoung" sort="Poo, Haryoung" uniqKey="Poo H" first="Haryoung" last="Poo">Haryoung Poo</name>
<affiliation wicri:level="1"><nlm:affiliation>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Scientific reports</title>
<idno type="eISSN">2045-2322</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Animals</term>
<term>Antigen Presentation (immunology)</term>
<term>Antigens, Viral (immunology)</term>
<term>Chitosan (analogs & derivatives)</term>
<term>Chitosan (chemistry)</term>
<term>Cross Reactions (immunology)</term>
<term>Dendritic Cells (immunology)</term>
<term>Dendritic Cells (metabolism)</term>
<term>Disease Models, Animal</term>
<term>Ferrets</term>
<term>Histocompatibility Antigens Class I (immunology)</term>
<term>Histocompatibility Antigens Class I (metabolism)</term>
<term>Humans</term>
<term>Immunity, Cellular</term>
<term>Immunogenicity, Vaccine</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza Vaccines (chemistry)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Mice</term>
<term>Orthomyxoviridae Infections (mortality)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Phagosomes (metabolism)</term>
<term>Polyglutamic Acid (analogs & derivatives)</term>
<term>Polyglutamic Acid (chemistry)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acide polyglutamique ()</term>
<term>Acide polyglutamique (analogues et dérivés)</term>
<term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Antigènes d'histocompatibilité de classe I (immunologie)</term>
<term>Antigènes d'histocompatibilité de classe I (métabolisme)</term>
<term>Antigènes viraux (immunologie)</term>
<term>Cellules dendritiques (immunologie)</term>
<term>Cellules dendritiques (métabolisme)</term>
<term>Chitosane ()</term>
<term>Chitosane (analogues et dérivés)</term>
<term>Furets</term>
<term>Grippe humaine ()</term>
<term>Humains</term>
<term>Immunité cellulaire</term>
<term>Immunogénicité des vaccins</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Infections à Orthomyxoviridae (mortalité)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Phagosomes (métabolisme)</term>
<term>Présentation d'antigène (immunologie)</term>
<term>Réactions croisées (immunologie)</term>
<term>Souris</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Vaccins antigrippaux ()</term>
<term>Vaccins antigrippaux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Chitosan</term>
<term>Polyglutamic Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Chitosan</term>
<term>Influenza Vaccines</term>
<term>Polyglutamic Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term>
<term>Histocompatibility Antigens Class I</term>
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Histocompatibility Antigens Class I</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Acide polyglutamique</term>
<term>Chitosane</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes d'histocompatibilité de classe I</term>
<term>Antigènes viraux</term>
<term>Cellules dendritiques</term>
<term>Présentation d'antigène</term>
<term>Réactions croisées</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antigen Presentation</term>
<term>Cross Reactions</term>
<term>Dendritic Cells</term>
<term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Dendritic Cells</term>
<term>Phagosomes</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antigènes d'histocompatibilité de classe I</term>
<term>Cellules dendritiques</term>
<term>Phagosomes</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Ferrets</term>
<term>Humans</term>
<term>Immunity, Cellular</term>
<term>Immunogenicity, Vaccine</term>
<term>Mice</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Acide polyglutamique</term>
<term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Chitosane</term>
<term>Furets</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Immunité cellulaire</term>
<term>Immunogénicité des vaccins</term>
<term>Infections à Orthomyxoviridae</term>
<term>Modèles animaux de maladie humaine</term>
<term>Souris</term>
<term>Vaccins antigrippaux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In 2009, the global outbreak of an influenza pandemic emphasized the need for an effective vaccine adjuvant. In this study, we examined the efficacy of poly-γ-glutamic acid/chitosan (PC) nanogel as an adjuvant for the influenza vaccine. PC nanogel significantly enhanced antigen-specific cross-presentation and cytotoxic T lymphocyte (CTL) activity. Compared with alum, the protective efficacy of the pandemic H1N1 influenza (pH1N1) vaccine was substantially increased by PC nanogel, with increased hemagglutination-inhibition titers, CTL activity, and earlier virus clearance after homologous and heterosubtypic [A/Philippines/2/82 (H3N2)] virus challenges. However, CD8<sup>+</sup>
 T cell-depleted mice displayed no protection against the heterosubtypic virus challenge after immunization with PC nanogel-adjuvanted pH1N1 vaccine. We also observed that using PC nanogel as a vaccine adjuvant had a dose-sparing effect and significantly enhanced the long-lasting protection of the pH1N1 vaccine. Together, these results suggest that PC nanogel is a promising vaccine adjuvant that could broadly prevent influenza virus infection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28322289</PMID>
<DateCompleted><Year>2018</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>7</Volume>
<PubDate><Year>2017</Year>
<Month>03</Month>
<Day>21</Day>
</PubDate>
</JournalIssue>
<Title>Scientific reports</Title>
<ISOAbbreviation>Sci Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.</ArticleTitle>
<Pagination><MedlinePgn>44839</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/srep44839</ELocationID>
<Abstract><AbstractText>In 2009, the global outbreak of an influenza pandemic emphasized the need for an effective vaccine adjuvant. In this study, we examined the efficacy of poly-γ-glutamic acid/chitosan (PC) nanogel as an adjuvant for the influenza vaccine. PC nanogel significantly enhanced antigen-specific cross-presentation and cytotoxic T lymphocyte (CTL) activity. Compared with alum, the protective efficacy of the pandemic H1N1 influenza (pH1N1) vaccine was substantially increased by PC nanogel, with increased hemagglutination-inhibition titers, CTL activity, and earlier virus clearance after homologous and heterosubtypic [A/Philippines/2/82 (H3N2)] virus challenges. However, CD8<sup>+</sup>
 T cell-depleted mice displayed no protection against the heterosubtypic virus challenge after immunization with PC nanogel-adjuvanted pH1N1 vaccine. We also observed that using PC nanogel as a vaccine adjuvant had a dose-sparing effect and significantly enhanced the long-lasting protection of the pH1N1 vaccine. Together, these results suggest that PC nanogel is a promising vaccine adjuvant that could broadly prevent influenza virus infection.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Jihyun</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shim</LastName>
<ForeName>Sang-Mu</ForeName>
<Initials>SM</Initials>
<AffiliationInfo><Affiliation>Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nguyen</LastName>
<ForeName>Thi Quyen</ForeName>
<Initials>TQ</Initials>
<AffiliationInfo><Affiliation>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Biotechnology, University of Science and Technology, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Eun-Ha</ForeName>
<Initials>EH</Initials>
<AffiliationInfo><Affiliation>Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>College of Medicine, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Kwang</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>BioLeaders Corporation, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lim</LastName>
<ForeName>Yong Taik</ForeName>
<Initials>YT</Initials>
<AffiliationInfo><Affiliation>Sungkyunkwan Advanced Institute of Nanotechnology (SAINT) and Department of Chemical Engineering, Sungkyunkwan University Suwon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sung</LastName>
<ForeName>Moon-Hee</ForeName>
<Initials>MH</Initials>
<AffiliationInfo><Affiliation>BioLeaders Corporation, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Bio and Fermentation Convergence Technology, Kookmin University, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Webby</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Division of Virology, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Poo</LastName>
<ForeName>Haryoung</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Biotechnology, University of Science and Technology, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>03</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Sci Rep</MedlineTA>
<NlmUniqueID>101563288</NlmUniqueID>
<ISSNLinking>2045-2322</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000594594">chitosan-poly(gamma-glutamic acid)</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>25513-46-6</RegistryNumber>
<NameOfSubstance UI="D011099">Polyglutamic Acid</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9012-76-4</RegistryNumber>
<NameOfSubstance UI="D048271">Chitosan</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017951" MajorTopicYN="N">Antigen Presentation</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D048271" MajorTopicYN="N">Chitosan</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010588" MajorTopicYN="N">Phagosomes</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011099" MajorTopicYN="N">Polyglutamic Acid</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>09</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>02</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>3</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>3</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>11</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28322289</ArticleId>
<ArticleId IdType="pii">srep44839</ArticleId>
<ArticleId IdType="doi">10.1038/srep44839</ArticleId>
<ArticleId IdType="pmc">PMC5359587</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2006 Jan;12(1):61-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16494719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2007 Jul;5(7):505-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17558426</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biotechnol Lett. 2006 Aug;28(16):1241-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16816893</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 Dec 15;187(12):6249-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22095716</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Sep 25;27(42):5896-905</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19647814</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2012 Mar 16;148(6):1284-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22424235</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2011 Jul;85(13):6275-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21507962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2014 Jul 31;158(3):506-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25083866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Biodivers. 2010 Jun;7(6):1555-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20564573</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Cell Biol. 2004 Oct;82(5):488-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15479434</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Rec. 2005;5(6):352-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16278834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2006 Jan;24(1):5-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16413916</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mech Ageing Dev. 2002 Apr 30;123(8):1167-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12044966</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2004 Sep 9;22(27-28):3658-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15315845</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Today. 1998 Aug;19(8):368-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9709505</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2001 Nov;1(2):126-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11905820</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Vet Sci Comp Med. 1989;33:301-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2467538</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2008 Sep 1;198(5):642-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18576945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2008 Nov;2(6):251-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19453402</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009;4(3):e4667</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19252744</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccines (Basel). 2014 Apr 25;2(2):323-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26344622</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Macromol Biosci. 2005 Jul 14;5(7):598-602</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15991216</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Nov 23;28(50):7897-906</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20934457</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2004 Feb 15;172(4):2453-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14764717</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2012 Jul 13;12(8):557-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22790179</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Jan 30;26(5):589-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18180081</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2004 Apr;21(4):671-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15139524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2007 Mar 1;178(5):2979-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17312143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2015 Mar;14(3):167-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25722244</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 1993 Spring;6(1):55-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8476508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Mater. 2013 Nov;12(11):978-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24150416</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Immunol Immunother. 2009 Nov;58(11):1781-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19294383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Pharmacol. 2001 Aug;53(8):1047-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11518015</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Pharm Res. 2012 Aug;35(8):1297-316</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22941474</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccines (Basel). 2015 Apr 16;3(2):320-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26343190</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Jan;12(1):48-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16494717</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1992 Aug 15;149(4):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1354233</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2009 Nov 26;462(7272):449-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19940915</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2012;8(12):e1003076</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23271970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2006 May 20;367(9523):1657-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16714186</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Small. 2011 Dec 2;7(23):3281-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22009658</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Jun 18;360(25):2605-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19423869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Nov 28;25(49):8270-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17977633</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Drug Deliv Rev. 2003 Feb 24;55(3):329-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12628320</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2016 Mar 1;126(3):799-808</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26928033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Cell Biol. 2000 Apr;78(2):110-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10762410</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2010 Aug;8(8):578-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20581859</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Rev. 2015 Oct 14;115(19):11109-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26154342</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Angew Chem Int Ed Engl. 2013 Jul 22;52(30):7684-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23765547</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2013 Dec;9(12):2584-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23978910</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Nanomedicine. 2014 Dec 30;10:229-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25565816</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hyg (Lond). 1972 Dec;70(4):767-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4509641</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 1986;128:1-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3533447</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2002 May 31;20 Suppl 3:S34-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12184362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(8):e23698</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21887299</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2006 Mar 30;354(13):1343-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16571878</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2015 Sep 1;195(5):2472-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26216889</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1999 Feb 1;254(1):50-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9927573</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000440 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000440 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:28322289
   |texte=   Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:28322289" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.

Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki